The CETP TaqIB polymorphism is associated with the risk of sudden death in type 2 diabetic patients

Diabetes Care

Volumn 30, Issue 11, 2007, Pages 2863-2867

  Porchay Baldérelli, Isabelle ^a,b   Péan, Franck ^a,b   Bellili, Naïma ^a,b   Jaziri, Riphed ^a,b   Marre, Michel ^a,b,c   Fumeron, Frédéric ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RAMIPRIL;

AGED; ARTICLE; CARDIOVASCULAR RISK; CETP GENE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE; GENOTYPE; HAZARD RATIO; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPORTIONAL HAZARDS MODEL; PROTEINURIA; SINGLE NUCLEOTIDE POLYMORPHISM; SUDDEN DEATH;

CHOLESTEROL ESTER TRANSFER PROTEINS; CORONARY DISEASE; DEATH, SUDDEN; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FRANCE; GENOTYPE; HETEROZYGOTE DETECTION; HOMOZYGOTE; HUMANS; POLYMORPHISM, GENETIC; RISK ASSESSMENT;

EID: 36048943607     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc07-0869     Document Type: Article

References (32)

1. Pyorala K, Laakso M, Uusitupa M: Diabetes and atherosclerosis: an epidemiological view. Diabetes Metab Rev 3:463-524, 1987
2. Balkau B, Jouven X, Ducimetiere P, Eschwege E: Diabetes as a risk factor for sudden death. Lancet 345:1968-1969, 1999
3. Curb JD, Rodriguez BL, Burchfiel CM, Abbott RD, Chiu D, Yano K: Sudden death, impaired glucose tolerance, and diabetes in Japanese-American men. Circulation 91:2591-2595, 1995
4. Wilson PW: Established risk factors and coronary artery disease: the Framingham Study. Am J Hypertens 7:7S-12S, 1994
5. Suarez GA, Clark VM, Norell JE, Kottke TE, Callahan MJ, O'Brien PC, Low PA, Dyck PJ: Sudden cardiac death in diabetes mellitus: risk factors in the Rochester diabetic neuropathy study. J Neurol Neurosurg Psychiatry 76:240-245, 2005
6. Dunn FL Hyperlipidemia in diabetes mellitus. Diabetes Metab Rev 6:47-61, 1990
7. Yamashita S, Hirano K, Sakai N, Matsuzawa Y: Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein. Biochim Biophys Acta 1529:257-275, 2000
8. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, Lie KI, Kastelein JJ: The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med 338:86-93, 1998
9. Durlach A, Clavel C, Girard-Globa A, Durlach V: Sex-dependent association of a genetic polymorphism of cholesteryl ester transfer protein with high-density lipoprotein cholesterol and macrovascular pathology in type II diabetic patients. J. Clin Endocrinol Metab 84:3656-3659, 1999
10. Dachet C, Poirier O, Cambien F, Luc G, Chapman J, Rouis M: New functional promoter polymorphism, C-629A, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and HDL cholesterol levels: role of Sp1/Sp3 in transcriptional regulation. Arterioscler Thromb Vasc Biol 20:507-515, 2000
11. Boekholdt SM, Sacks FM, Jukema JW, Shepherd J, Freeman DJ, McMahon AD, Cambien F, Nicaud V, de Grooth GJ, Talmud PJ, Humphries SE, Miller GJ, Eiriksdottir G, Gudnason V, Kauma H, Kakko S, Savolainen MJ, Arca M, Montali A, Liu S, Lanz HJ, Zwinderman AH, Kuivenhoven JA, Kastelein JJ: Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13 677 Subjects. Circulation 111:278-287, 2005
12. Kawasaki I, Tahara H, Emoto M, Shoji T, Nishizawa Y: Relationship between TaqIB cholesteryl ester transfer protein gene polymorphism and macrovascular complications in Japanese patients with type 2 diabetes. Diabetes 51:871-874, 2002
13. Ordovas JM, Cupples LA, Corella D, Otvos JD, Osgood D, Martinez A, Lahoz C, Coltell O, Wilson PW, Schaefer EJ: Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler Thromb Vasc Biol 20:1323-1329, 2000
14. Liu S, Schmitz C, Stampfer MJ, Sacks F, Hennekens CH, Lindpaintner K, Ridker PM, Liu S: A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men. Atherosclerosis 161:469-474, 2002
15. Fazio S, Linton MF: Sorting out the complexities of reverse cholesterol transport: CETP polymorphisms, HDL, and coronary disease. J Clin Endocrinol Metab 91:3273-3275, 2006
16. Borggreve SE, Hillege HL, Wolffenbuttel BH, de Jong PE, Zuurman MW, van der Steege G, van Tol A, Dullaart RP, PREVEND Study Group: An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab 91:3382-3388, 2006
17. Passa P, Chatellier G: The DIAB-HYCAR Study. Diabetologia 39:1662-1667, 1996
18. Lièvre M, Marre M, Chatellier G, Plouin P, Réglier J, Richardson L, Bugnard F, Vasmant D: The Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) study: design, organization, and patient recruitment: DIABHYCAR Study Group. Control Clin Trials 21:383-396, 2000
19. Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Menard J: Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 328:495, 2004
20. Hetet G, Elbaz A, Gariepy J, Nicaud V, Arveiler D, Morrison C, Kee F, Evans A, Simon A, Amarenco P, Cambien F, Grandchamp B: Association studies between haemochromatosis gene mutations and the risk of cardiovascular diseases. Eur J Clin Invest 31:382-388, 2001
21. Fumeron F, Betoulle D, Luc G, Behague I, Ricard S, Poirier O, Jemaa R, Evans A, Arveiler D, Marques-Vidal P, Bard JM, Fruchard JC, Ducimetiere P, Apfelbaum M, Cambien F: Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. J Clin Invest 96:1664-1671, 1995
22. Meguro S, Takei I, Murata M, Hirose H, Takei N, Mitsuyoshi Y, Ishii K, Oguchi S, Shinohara J, Takeshita E, Watanabe K, Saruta T: Cholesteryl ester transfer protein polymorphism associated with macroangiopathy in Japanese patients with type 2 diabetes. Atherosclerosis 156:151-156, 2001
23. Relvas WG, Izar MC, Helfenstein T, Fonseca MI, Colovati M, Oliveira A, Ihara SS, Han SW, Las Casas AA, Fonseca FA: Relationship between gene polymorphisms and prevalence of myocardial infarction among diabetic and non-diabetic subjects. Atherosclerosis 178:101-105, 2005
24. Blankenberg S, Rupprecht HJ, Bickel C, Jiang XC, Poirier O, Lackner KJ, Meyer J, Cambien F, Tiret L: Common genetic variation of the cholesteryl ester transfer protein gene strongly predicts future cardiovascular death in patients with coronary artery disease. J Am Coll Cardiol 41:1983-1989, 2003
25. Asselbergs FW, Moore JH, van den Berg MP, Rimm EB, de Boer RA, Dullaart RP, Navis G, van Gilst WH: A role for CETP TaqIB polymorphism in determining susceptibility to atrial fibrillation: a nested case control study. BMC Med Genet 7:39, 2006
26. Jouven X, Desnos M, Guerot C, Ducimetière P: Idiopathic atrial fibrillation as a risk factor for mortality: the Paris Prospective Study I. Eur Heart J 20:896-899, 1999
27. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D: Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98:946-952, 1998
28. Klerkx AH, El Harchaoui K, van der Steeg WA Boekholdt SM, Stroes ES, Kastelein JJ, Kuivenhoven JA: Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis. Arterioscler Thromb Vasc Biol 26:706-715, 2006
29. Barter PJ, Kastelein JJP: Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am Coll Cardiol 47:492-499, 2006
30. Editorial: Cholesterol: the good, the bad, and the stopped trials. Lancet 368:2034, 2006
31. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM, ILLUSTRATE Investigators: Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356:1304-1316, 2007
32. Tall AR: CETP inhibitors to increase HDL cholesterol levels: effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356:1364-1366, 2007